The marketing of a popular as well as a costly colorectal cancer drug, named Erbitux was banned in Canada since the distributors can't afford the price it needs.
The drug got approval from 'Health Canada' nine months back. Since the price allotted by the Patented Medicine Prices Review Board was not compromised by Bristol-Myers Squibb Canada the move was blocked.
A full course of drug therapy costs about $56,000 - estimates the Cancer Advocacy Coalition of Canada.
Some have proven that Erbitux help to shrink tumour growth or sometimes delay it, whenever used in combination.
Due to lack of sufficient supply Mr. Cohen under Ontario's Freedom of Information and Protection of Privacy Act, Ontario patients requiring Erbitux are also being sent to the Memorial Sloan-Kettering Cancer Center.
Canadian Cancer Society declared an approximate of 8,500 were expected to die of the disease and nearly 20,000 people in Canada were estimated to have colorectal cancer.
The Patented Medicine Prices Review Board scrutinizes the others like Germany, France, Italy, Sweden, Switzerland, the United Kingdom and the United States and put Canada at the top for drug costs.
Although, there seems to have disputes in drug marketing some are getting the drug paying by themselves.